\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ unremarkable\ \(0\)\
\-\ lab\\:\\ \\ esr\\-25\\,\\ crp\\-1\\.40\ \(0\)\
\-\ patient\\ was\\ started\\ on\\ prednisone\\ 50\\ mg\\ daily\\ by\\ her\\ ophthalmologist\\ in\\ consultation\\ with\\ rheumatology\\.\ \(0\)\
\-\ there\\ is\\ diffuse\\ abnormal\\ fdg\\ uptake\\ involving\\ the\\ aortic\\ arch\\ and\\ its\\ major\\ branches\\.\\ additionally\\,\\ there\\ is\\ low\\ level\\ fdg\\ uptake\\ involving\\ the\\ descending\\ thoracic\\ aorta\\,\\ as\\ well\\ as\\ the\\ abdominal\\ aorta\\.\\ the\\ diffuse\\ abnormal\\ uptake\\ continues\\ to\\ involve\\ the\\ external\\ iliac\\ artery\\ and\\ into\\ the\\ superficial\\ femoral\\ arteries\\ bilaterally\\.\ \(0\)\
\-\ giant\\ cell\\ arteritis\ \(7\)\
\-\ giant\\ cell\\ arteritis\\ \\ \\ \\ \\ \ \(0\)\
\-\ takayasu\\ arteritis\\-imaging\\ would\\ be\\ essentially\\ the\\ same\\ as\\ giant\\ cell\\ arteritis\\,\\ however\\ can\\ be\\ generally\\ distinguished\\ based\\ upon\\ demographics\\.\\ \\ giant\\ cell\\ arteritis\\ occurs\\ almost\\ exclusively\\ in\\ older\\ patients\\,\\ while\\ takaysu\\ arteritis\\ occurs\\ in\\ patients\\ aged\\ 20\\-40\\.\\ \\ \ \(0\)\
\-\ atherosclerosis\\-pet\\ would\\ show\\ mild\\ heterogeneous\\ enhancement\\ with\\ skipped\\ areas\\,\\ while\\ more\\ severe\\ atherosclerosis\\ could\\ demonstrate\\ ulcerated\\ plaques\\.\ \(0\)\
\-\ vascular\\ thrombosis\\-would\\ show\\ increased\\ fdg\\ uptake\\ in\\ the\\ lumen\\ rather\\ than\\ the\\ vessel\\ wall\\.\ \(0\)\
\-\ 81\\ year\\ old\\ female\\ history\\ of\\ vasculitis\\ s\\/p\\ long\\-term\\ corticosteroid\\ treatment\\ and\\ colon\\ cancer\\ s\\/p\\ resection\\ presents\\ with\\ increasing\\ esr\\/crp\\ on\\ pre\\-operative\\ evaluation\\ for\\ cataract\\ surgery\\.\ \(0\)\
\-\ this\\ patient\\ had\\ a\\ previous\\ biopsy\\ proven\\ diagnosis\\ of\\ giant\\ cell\\ arteritis\\,\\ but\\ had\\ concluded\\ her\\ extended\\ course\\ of\\ corticosteroids\\.\\ \\ \ \(0\)\
\-\ determining\\ disease\\ recurrence\\ can\\ be\\ difficult\\,\\ especially\\ in\\ a\\ patient\\ such\\ as\\ this\\ who\\ had\\ no\\ recurrence\\ in\\ symptoms\\ and\\ whose\\ only\\ sign\\ was\\ increasing\\ esr\\/crp\\,\\ which\\ are\\ imperfect\\ markers\\ for\\ disease\\ activity\\.\\ \\ imaging\\ can\\ be\\ helpful\\ in\\ assessing\\ for\\ recurrence\\,\\ though\\ imaging\\ findings\\ do\\ not\\ necessarily\\ correlate\\ with\\ disease\\ activity\\,\\ as\\ low\\ level\\ changes\\ can\\ persist\\ on\\ imaging\\ despite\\ clinically\\ inactive\\ disease\\.\\ \\ \ \(0\)\
\-\ in\\ this\\ case\\ there\\ was\\ clearly\\ active\\ disease\\ with\\ diffuse\\ increased\\ vascular\\ uptake\\ in\\ large\\ arteries\\,\\ from\\ the\\ carotids\\ and\\ vertebral\\ arteries\\ through\\ the\\ aorta\\ and\\ into\\ the\\ external\\ iliacs\\ and\\ superficial\\ femorals\\.\\ \\ \ \(0\)\
\-\ such\\ diffuse\\ activity\\ was\\ previously\\ thought\\ to\\ be\\ rare\\,\\ but\\ with\\ increased\\ use\\ of\\ imaging\\ such\\ as\\ mri\\ and\\ pet\\ in\\ recent\\ years\\,\\ it\\ is\\ now\\ evident\\ that\\ giant\\ cell\\ arteritis\\ is\\ a\\ systemic\\ disease\\.\\ \\ in\\ a\\ prospective\\ study\\ of\\ 35\\ patients\\ with\\ biopsy\\ proven\\ giant\\ cell\\ arteritis\\ by\\ blockmans\\ et\\ al\\,\\ increased\\ vascular\\ fdg\\ uptake\\ was\\ noted\\ on\\ pet\\ in\\ 29\\ patients\\ \\(83\\%\\)\\,\\ with\\ subclavian\\ arteries\\ involved\\ in\\ 74\\%\\,\\ the\\ aorta\\ in\\ greater\\ than\\ 50\\%\\ and\\ the\\ femoral\\ arteries\\ in\\ 37\\%\\.\ \(0\)\
\-\ in\\ this\\ patient\\ with\\ recent\\ history\\ of\\ colon\\ cancer\\,\\ pet\\ also\\ served\\ as\\ surveillance\\ for\\ disease\\ recurrence\\.\\ \\ her\\ visceral\\ organs\\ did\\ not\\ show\\ any\\ increased\\ fdg\\ uptake\\ to\\ suggest\\ recurrence\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ arteritis\\:\\ 0\\.10350841381389245\ \(0\)\
\-\ giant\\:\\ 0\\.06561564101872112\ \(0\)\
\-\ fdg\\:\\ 0\\.06329637683308674\ \(0\)\
\-\ uptake\\:\\ 0\\.05413413205662753\ \(0\)\
\-\ recurrence\\:\\ 0\\.04245924930221087\ \(0\)\
\-\ arteries\\:\\ 0\\.040289336728200245\ \(0\)\
\-\ esr\\/crp\\:\\ 0\\.040161815143355345\ \(0\)\
\-\ cell\\:\\ 0\\.03680566054913532\ \(0\)\
\-\ aorta\\:\\ 0\\.03342163049797763\ \(0\)\
\-\ pet\\:\\ 0\\.03064773405703987\ \(0\)\
\-\ increased\\:\\ 0\\.023809621660588334\ \(0\)\
\-\ diffuse\\:\\ 0\\.023571821597952753\ \(0\)\
\-\ disease\\:\\ 0\\.02227144143168549\ \(0\)\
\-\ proven\\:\\ 0\\.02216070480813244\ \(0\)\
\-\ activity\\:\\ 0\\.021909202474589103\ \(0\)\
\-\ superficial\\:\\ 0\\.020806483744497214\ \(0\)\
\-\ as\\:\\ 0\\.020610575264826642\ \(0\)\
\-\ patients\\:\\ 0\\.020151021406524153\ \(0\)\
\-\ esr\\-25\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ crp\\-1\\.40\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ arteritis\\-imaging\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ takaysu\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ 20\\-40\\.\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ atherosclerosis\\-pet\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ thrombosis\\-would\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ imperfect\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ femorals\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ blockmans\\:\\ 0\\.020080907571677672\ \(0\)\
\-\ vascular\\:\\ 0\\.01914671937077697\ \(0\)\
\-\ skipped\\:\\ 0\\.018501984609126543\ \(0\)\
\-\ such\\:\\ 0\\.018255121570666416\ \(0\)\
\-\ imaging\\:\\ 0\\.018242130518957653\ \(0\)\
\-\ \\%\\:\\ 0\\.018162378435954512\ \(0\)\
\-\ show\\:\\ 0\\.017925894768735486\ \(0\)\
\-\ can\\:\\ 0\\.017660340341403822\ \(0\)\
\-\ iliacs\\:\\ 0\\.017578373884506577\ \(0\)\
\-\ served\\:\\ 0\\.017578373884506577\ \(0\)\
\-\ her\\:\\ 0\\.017558621811969946\ \(0\)\
\-\ external\\:\\ 0\\.016554600791227395\ \(0\)\
\-\ s\\/p\\:\\ 0\\.016329885226022373\ \(0\)\
\-\ occurs\\:\\ 0\\.015978363218976277\ \(0\)\
\-\ increasing\\:\\ 0\\.015955865352732166\ \(0\)\
\-\ in\\:\\ 0\\.015358441189622048\ \(0\)\
\-\ inactive\\:\\ 0\\.015344138684024287\ \(0\)\
\-\ colon\\:\\ 0\\.015288988199646192\ \(0\)\
\-\ cataract\\:\\ 0\\.015075840197335485\ \(0\)\
\-\ be\\:\\ 0\\.015008618716901245\ \(0\)\
\-\ 50\\:\\ 0\\.014810924904983164\ \(0\)\
\-\ femoral\\:\\ 0\\.014810924904983164\ \(0\)\
\-\ ophthalmologist\\:\\ 0\\.014420527959404322\ \(0\)\
\-\ ulcerated\\:\\ 0\\.014420527959404322\ \(0\)\
\-\ rheumatology\\:\\ 0\\.014238198329168476\ \(0\)\
\-\ carotids\\:\\ 0\\.014238198329168476\ \(0\)\
\-\ takayasu\\:\\ 0\\.014069387458658858\ \(0\)\
\-\ demographics\\:\\ 0\\.014069387458658858\ \(0\)\
\-\ concluded\\:\\ 0\\.013912228298096328\ \(0\)\
\-\ whose\\:\\ 0\\.013912228298096328\ \(0\)\
\-\ necessarily\\:\\ 0\\.013912228298096328\ \(0\)\
\-\ would\\:\\ 0\\.013854063227435489\ \(0\)\
\-\ biopsy\\:\\ 0\\.013811814312695948\ \(0\)\
\-\ involving\\:\\ 0\\.013660169767668763\ \(0\)\
\-\ exclusively\\:\\ 0\\.013256916060165163\ \(0\)\
\-\ assessing\\:\\ 0\\.013256916060165163\ \(0\)\
\-\ distinguished\\:\\ 0\\.013145776734038894\ \(0\)\
\-\ recent\\:\\ 0\\.013087558309065134\ \(0\)\
\-\ markers\\:\\ 0\\.012938551726736556\ \(0\)\
\-\ visceral\\:\\ 0\\.012938551726736556\ \(0\)\
\-\ aged\\:\\ 0\\.012841604996853193\ \(0\)\
\-\ determining\\:\\ 0\\.012841604996853193\ \(0\)\
\-\ prospective\\:\\ 0\\.012841604996853193\ \(0\)\
\-\ cancer\\:\\ 0\\.01279801942762991\ \(0\)\
\-\ pre\\-operative\\:\\ 0\\.012748616398857169\ \(0\)\
\-\ 81\\:\\ 0\\.012659275366617347\ \(0\)\
\-\ had\\:\\ 0\\.012600340450392085\ \(0\)\
\-\ persist\\:\\ 0\\.012573306510164394\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.012490464496107731\ \(0\)\
\-\ atherosclerosis\\:\\ 0\\.012258613256221759\ \(0\)\
\-\ while\\:\\ 0\\.01224897147996498\ \(0\)\
\-\ correlate\\:\\ 0\\.012116197864464733\ \(0\)\
\-\ surveillance\\:\\ 0\\.012116197864464733\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.011855582030346864\ \(0\)\
\-\ 83\\:\\ 0\\.011855582030346864\ \(0\)\
\-\ prednisone\\:\\ 0\\.011513253549596663\ \(0\)\
\-\ extended\\:\\ 0\\.011262682034302068\ \(0\)\
\-\ was\\:\\ 0\\.011256008225668416\ \(0\)\
\-\ level\\:\\ 0\\.01122045115101108\ \(0\)\
\-\ organs\\:\\ 0\\.01116969343630604\ \(0\)\
\-\ 74\\:\\ 0\\.01112458494588194\ \(0\)\
\-\ abnormal\\:\\ 0\\.011102925923985927\ \(0\)\
\-\ \\,\\:\\ 0\\.011099729337838662\ \(0\)\
\-\ essentially\\:\\ 0\\.010911541533556602\ \(0\)\
\-\ consultation\\:\\ 0\\.010871223590277786\ \(0\)\
\-\ plaques\\:\\ 0\\.010871223590277786\ \(0\)\
\-\ low\\:\\ 0\\.010825366983446012\ \(0\)\
\-\ long\\-term\\:\\ 0\\.010754382372994073\ \(0\)\
\-\ mg\\:\\ 0\\.01067969029367063\ \(0\)\
\-\ branches\\:\\ 0\\.010643243046867803\ \(0\)\
\-\ than\\:\\ 0\\.010200678154525165\ \(0\)\
\-\ continues\\:\\ 0\\.010156741679446257\ \(0\)\
\-\ 29\\:\\ 0\\.010156741679446257\ \(0\)\
\-\ daily\\:\\ 0\\.0100707728229933\ \(0\)\
\-\ helpful\\:\\ 0\\.0100707728229933\ \(0\)\
\-\ clearly\\:\\ 0\\.010015211426355124\ \(0\)\
\-\ vasculitis\\:\\ 0\\.009960973046642783\ \(0\)\
\-\ subclavian\\:\\ 0\\.009934330587045535\ \(0\)\
\-\ older\\:\\ 0\\.009805601178700794\ \(0\)\
\-\ 37\\:\\ 0\\.0097807058016343\ \(0\)\
\-\ iliac\\:\\ 0\\.009707611691038627\ \(0\)\
\-\ lab\\:\\ 0\\.009523438350197864\ \(0\)\
\-\ descending\\:\\ 0\\.009501429441515092\ \(0\)\
\-\ almost\\:\\ 0\\.009415460585062136\ \(0\)\
\-\ lumen\\:\\ 0\\.009373663002674445\ \(0\)\
\-\ systemic\\:\\ 0\\.009312370399212204\ \(0\)\
\-\ vessel\\:\\ 0\\.009272406140326305\ \(0\)\
\-\ into\\:\\ 0\\.009263445867697982\ \(0\)\
\-\ rather\\:\\ 0\\.009252683901731512\ \(0\)\
\-\ involve\\:\\ 0\\.009175459410442944\ \(0\)\
\-\ major\\:\\ 0\\.0091007673311195\ \(0\)\
\-\ despite\\:\\ 0\\.00904631284170366\ \(0\)\
\-\ though\\:\\ 0\\.009028446833819774\ \(0\)\
\-\ thought\\:\\ 0\\.008958351939362477\ \(0\)\
\-\ 35\\:\\ 0\\.008958351939362477\ \(0\)\
\-\ evident\\:\\ 0\\.008907160923754142\ \(0\)\
\-\ arch\\:\\ 0\\.008760148347130974\ \(0\)\
\-\ generally\\:\\ 0\\.008760148347130974\ \(0\)\
\-\ this\\:\\ 0\\.008757514472110551\ \(0\)\
\-\ pe\\:\\ 0\\.008744384240423515\ \(0\)\
\-\ there\\:\\ 0\\.008690539110239103\ \(0\)\
\-\ started\\:\\ 0\\.00868239662419371\ \(0\)\
\-\ clinically\\:\\ 0\\.008534428751130448\ \(0\)\
\-\ difficult\\:\\ 0\\.00852014717251178\ \(0\)\
\-\ do\\:\\ 0\\.008450052278054482\ \(0\)\
\-\ additionally\\:\\ 0\\.008436288463803997\ \(0\)\
\-\ but\\:\\ 0\\.008302976314503588\ \(0\)\
\-\ suggest\\:\\ 0\\.008290133693377378\ \(0\)\
\-\ al\\:\\ 0\\.008251848685822979\ \(0\)\
\-\ previously\\:\\ 0\\.008177156606499538\ \(0\)\
\-\ involved\\:\\ 0\\.008164942613011187\ \(0\)\
\-\ same\\:\\ 0\\.008023265601918008\ \(0\)\
\-\ especially\\:\\ 0\\.008011847511203785\ \(0\)\
\-\ et\\:\\ 0\\.007966739020779684\ \(0\)\
\-\ upon\\:\\ 0\\.0079556001021141\ \(0\)\
\-\ aortic\\:\\ 0\\.007879116513199284\ \(0\)\
\-\ patient\\:\\ 0\\.007804937867119708\ \(0\)\
\-\ vertebral\\:\\ 0\\.007703408702533617\ \(0\)\
\-\ use\\:\\ 0\\.007693483177775177\ \(0\)\
\-\ previous\\:\\ 0\\.007558884279438032\ \(0\)\
\-\ rare\\:\\ 0\\.007558884279438032\ \(0\)\
\-\ thoracic\\:\\ 0\\.007503547849895789\ \(0\)\
\-\ active\\:\\ 0\\.007431796899874442\ \(0\)\
\-\ based\\:\\ 0\\.0074229848798791805\ \(0\)\
\-\ its\\:\\ 0\\.007345174130878453\ \(0\)\
\-\ course\\:\\ 0\\.007345174130878453\ \(0\)\
\-\ greater\\:\\ 0\\.0073114267828485215\ \(0\)\
\-\ could\\:\\ 0\\.007181225384579845\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.007157619947141243\ \(0\)\
\-\ did\\:\\ 0\\.007028288476065885\ \(0\)\
\-\ sign\\:\\ 0\\.0067436138992347855\ \(0\)\
\-\ now\\:\\ 0\\.006654021844422887\ \(0\)\
\-\ for\\:\\ 0\\.006643354429546379\ \(0\)\
\-\ on\\:\\ 0\\.006595817880322807\ \(0\)\
\-\ areas\\:\\ 0\\.006549765765936371\ \(0\)\
\-\ by\\:\\ 0\\.006482327577425397\ \(0\)\
\-\ unremarkable\\:\\ 0\\.00644434263936688\ \(0\)\
\-\ study\\:\\ 0\\.0064046272365830504\ \(0\)\
\-\ bilaterally\\:\\ 0\\.006393406010305019\ \(0\)\
\-\ any\\:\\ 0\\.006129464767818437\ \(0\)\
\-\ resection\\:\\ 0\\.006070422905513026\ \(0\)\
\-\ severe\\:\\ 0\\.00598931617327108\ \(0\)\
\-\ only\\:\\ 0\\.005852873937323315\ \(0\)\
\-\ artery\\:\\ 0\\.005796195881795442\ \(0\)\
\-\ years\\:\\ 0\\.005715815801864425\ \(0\)\
\-\ evaluation\\:\\ 0\\.0056543024961886275\ \(0\)\
\-\ wall\\:\\ 0\\.005638175672525617\ \(0\)\
\-\ not\\:\\ 0\\.005625597593357336\ \(0\)\
\-\ changes\\:\\ 0\\.0055786969845901145\ \(0\)\
\-\ through\\:\\ 0\\.005528375896175099\ \(0\)\
\-\ however\\:\\ 0\\.005419972791792871\ \(0\)\
\-\ history\\:\\ 0\\.005376831606865983\ \(0\)\
\-\ enhancement\\:\\ 0\\.005217514273628783\ \(0\)\
\-\ \\:\\:\\ 0\\.005149315790390273\ \(0\)\
\-\ mild\\:\\ 0\\.005125862081847692\ \(0\)\
\-\ is\\:\\ 0\\.005123378390749209\ \(0\)\
\-\ who\\:\\ 0\\.005075098881871758\ \(0\)\
\-\ more\\:\\ 0\\.004868283164720196\ \(0\)\
\-\ abdominal\\:\\ 0\\.004865419676815752\ \(0\)\
\-\ symptoms\\:\\ 0\\.00485115598382264\ \(0\)\
\-\ surgery\\:\\ 0\\.004726649349340034\ \(0\)\
\-\ noted\\:\\ 0\\.0046137156912359764\ \(0\)\
\-\ demonstrate\\:\\ 0\\.004479389843583236\ \(0\)\
\-\ mri\\:\\ 0\\.0044721545670036895\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0044697479061057395\ \(0\)\
\-\ the\\:\\ 0\\.004408861015605379\ \(0\)\
\-\ well\\:\\ 0\\.004403373469176882\ \(0\)\
\-\ it\\:\\ 0\\.004375508848594571\ \(0\)\
\-\ case\\:\\ 0\\.00425855223887761\ \(0\)\
\-\ large\\:\\ 0\\.004256360892553712\ \(0\)\
\-\ findings\\:\\ 0\\.004143136527995352\ \(0\)\
\-\ female\\:\\ 0\\.004001731825621488\ \(0\)\
\-\ presents\\:\\ 0\\.0039764106959178265\ \(0\)\
\-\ treatment\\:\\ 0\\.003939901958088581\ \(0\)\
\-\ also\\:\\ 0\\.0038374022634855382\ \(0\)\
\-\ and\\:\\ 0\\.003690389639157098\ \(0\)\
\-\ which\\:\\ 0\\.0036335867590946438\ \(0\)\
\-\ a\\:\\ 0\\.0036136656202150454\ \(0\)\
\-\ that\\:\\ 0\\.0033621428896556337\ \(0\)\
\-\ to\\:\\ 0\\.002918460877742503\ \(0\)\
\-\ from\\:\\ 0\\.002884819392150825\ \(0\)\
\-\ are\\:\\ 0\\.0026534712358305275\ \(0\)\
\-\ with\\:\\ 0\\.0023987188720022952\ \(0\)\
\-\ year\\:\\ 0\\.002177916330917801\ \(0\)\
\-\ old\\:\\ 0\\.001993017304925409\ \(0\)\
\-\ no\\:\\ 0\\.001960009454906155\ \(0\)\
\-\ \\(\\:\\ 0\\.0016454709026056048\ \(0\)\
\-\ \\)\\:\\ 0\\.001625370597069032\ \(0\)\
\-\ of\\:\\ 0\\.0015923070724098646\ \(0\)\
\-\ \\.\\:\\ 0\\.0012938327507005475\ \(0\)\
